Seoulin Bioscience Co

Seoulin Bioscience Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Seoulin Bioscience Co (038070.KQ) as of Nov 4, 2026 is 580.91 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -160.40 % — a change of -462.17% (higher).

FCF Conversion

580.91 %

YoY

-462.17%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Seoulin Bioscience Co is 2025 580.91 % . FCF Conversion Rate (FCF/EBITDA) of Seoulin Bioscience Co was 2024 -160.40 % . It decreases by -462.17% higher compared to the previous year.

The Seoulin Bioscience Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
143.47 KRW
Jan 1, 2019
79.37 KRW
Jan 1, 2020
67.10 KRW
Jan 1, 2021
46.49 KRW
Jan 1, 2022
-49.84 KRW
Jan 1, 2023
37.13 KRW
Jan 1, 2024
-160.40 KRW
Jan 1, 2025
580.91 KRW
The Seoulin Bioscience Co FCF Conversion history
YEARFCF ConversionYoY
580.91 %-462.17%
-160.40 %-531.96%
37.13 %-174.51%
-49.84 %-207.19%
46.49 %-30.72%
67.10 %-15.46%
79.37 %-44.68%
143.47 %-139.83%
-360.25 %+229.07%
-109.48 %-634.22%
20.49 %-72.36%
74.14 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Seoulin Bioscience Co Stock analysis

What does Seoulin Bioscience Co do? SeouLin Bioscience Co., Ltd. generates revenue through the development and supply of reagents, including DNA chips for gene therapy, clinical diagnosis, organ transplantation, and biopsy, as well as stem cells for treating incurable diseases and Alzheimer's disease. The company markets these products under its brand MyLab and imports bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt for domestic sales. Additionally, SeouLin Bioscience operates a real estate rental business to diversify its income streams. The primary customers for MyLab reagents and stem cell therapies are healthcare providers, research institutions, and medical facilities requiring advanced diagnostic and therapeutic solutions. Domestic market distribution of imported bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt targets laboratories and hospitals seeking high-quality research tools. The real estate rental business serves commercial tenants in Seongnam, Gyeonggi-Do, where the company is headquartered. SeouLin Bioscience focuses on the lifescience sector, specifically targeting applications in gene therapy, clinical diagnostics, and regenerative medicine. Its product segments include DNA chips, stem cells, and next-generation biotechnology drugs, all under the MyLab brand. The company leverages strategic imports of bio research equipment to meet domestic demand for specialized laboratory tools. Seoulin Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seoulin Bioscience Co stock

FCF Conversion Rate (FCF/EBITDA) of Seoulin Bioscience Co is 580.91 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Seoulin Bioscience Co changed from -160.40 % to 580.91 %, representing a -462.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Seoulin Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Seoulin Bioscience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Seoulin Bioscience Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Seoulin Bioscience Co